Two drugs being developed in partnership with an American pharmaceutical company are likely to bring in millions for Lower Hutt company Industrial Research, new figures show.
IRL, with BioCryst, is developing two major drugs, to combat cancer and skin-flaking condition psoriasis.
BioCryst estimated the anti-cancer drug, Fodosine, would bring in US$450 million ($630 million) to US$670 million annually if it made it to market.
New drugs look lucrative
AdvertisementAdvertise with NZME.
